Efficacy of infantile hepatic hemangioma with propranolol treatment
Efficacy of infantile hepatic hemangioma with propranolol treatment
复制标题
普萘洛尔治疗小儿肝血管瘤的疗效
作者：
Mu;Hsi;C. Yeung
理由：肝血管瘤在婴儿期很少发现。尽管大多数病例没有症状，但其中一些可能会出现危及生命的情况。在这方面，必须尽早发现，以防止该疾病可能导致的不祥后果。患者担忧：一名2个月14天大的女婴在新生儿超声检查中偶然发现有多处肝脏病变。经过平安无事的怀孕过程后，她顺利足月出生。体检完全正常，产后生命体征稳定。诊断：婴儿多发性肝血管瘤。干预：进行高分辨率超声和腹部计算机断层扫描以明确诊断。普萘洛尔在3月龄7日龄开始，初始剂量为每天1.5mg/kg，逐渐增加至每天2.5mg/kg。治疗过程中未见明显不良反应。治疗后 10 天通过超声观察到临床症状迅速改善，体型减小。最终，4.5个月后，肝脏病变完全消失。普萘洛尔的剂量为每天 2.5mg/kg，持续服用至初始处方后 6 个月。结果：11 个月的随访未发现血管瘤复发的证据。教训：对于婴儿肝血管瘤，必须进行早期诊断和干预，以防止可能出现的不良后果。尽管该疾病的普萘洛尔治疗方案仍在制定中，但目前的报告强化了使用普萘洛尔作为治疗婴儿肝血管瘤的一线药物的建议。
Rationale: Hepatic hemangioma is rarely discovered during the infantile period. Although most of the cases are asymptomatic, some of them may suffer life-threatening situations. In this regard, early detection is mandatory for preventing the ominous consequences that might be culminated from the disease. Patient concerns: A 2-month-14-day-old female infant was found incidentally to have multiple hepatic lesions during a newborn ultrasound screen. She was born smoothly at term after a non-eventful pregnancy course. Physical examination was completely normal and postnatal vital signs were stable. Diagnosis: Infantile multiple hepatic hemangiomas. Intervention: High-resolution ultrasound and abdominal computer tomogram were conducted to confirm the diagnosis. Propranolol was started at the age of 3 months and 7 days old with an initial dosage of 1.5 mg/kg per day and increased gradually to 2.5 mg/kg per day. No obvious adverse effects were noted during the treatment course. Rapid clinical improvement with decreasing size was observed by ultrasound 10 days after the treatment. Eventually, hepatic lesions totally disappeared 4.5 months later. Propranolol in dosage of 2.5 mg/kg per day was continued until 6 months after the initial prescription. Outcomes: A period of 11-month follow-up revealed no evidence of recurrence of hemangiomas. Lessons: Early diagnosis and intervention are mandatory for infantile hepatic hemangiomas to prevent possible ominous consequences. Though the propranolol therapy protocol for the disease is still under developing, the current report strengthens the recommendation to use propranolol as the first-line medication for treating infantile hepatic hemangiomas.
关注异常的 ECL2 相互作用，产生具有前所未有的支架的 β2â 肾上腺素受体拮抗剂
影响因子：
3.4
作者：
Scharf;Zimmermann;Wilhelm;Waldhoer
通讯作者：
Waldhoer